The researchers found that 6317 adults received a diagnosis of diabetes. Among US adults, the weighted prevalence of diagnosed diabetes, type 1 diabetes, and type 2 diabetes was 9.7, 0.5, and 8.5%, respectively.
"Gestational diabetes defined by criteria that identify a larger group of women was associated with a maternal disorder of glucose metabolism," the authors write.
The authors searched for randomized placebo-controlled trials (December 1, 2008 to November 24, 2017) involving 3 pharmacologic classes of antidiabetic medications to compare the effects of these agents on the risk of hospitalization for HF in T2DM patients.
WHO guidelines recommend selecting sulfonylureas as the single best second-line agent for Type 2 Diabetes Mellitus (T2DM) patients.
"The decision to name sulfonylureas as the single best second-line agent largely reflects the prioritization of cost and the recognition that WHO guidelines must apply to low-resource settings," write the authors of an accompanying editorial.
The infection developed within several months of the patients starting SGLT2 therapy and the drug was discontinued in most cases. All patients required surgery and there was 1 reported death.
The researchers found that women who later developed GDM had significantly higher HbA1c at 8 to 13 gestational weeks than women without GDM (5.3 vs 5.1%).
PIONEER 5 (N=324) was a randomized, double-blind, placebo-controlled, parallel-group, 26-week trial that evaluated the safety and efficacy of oral semaglutide 14mg vs placebo in patients with type 2 diabetes and moderate renal impairment (eGFR 30 to 59mL/min/1.73m2) inadequately controlled with metformin, sulfonylurea alone or in combination with metformin, or basal insulin alone or in combination with metformin.
Basal insulin analogues do not differ significantly in providing glucose control.
The researchers found that both fT3 and fT3-to-fT4 ratio were positively correlated with GDM (adjusted odds ratios, 4.25 and 3.89 comparing the highest versus the lowest fT3 quartile at first and second trimester, respectively).
"This prospective evaluation of patients with hypotonic polyuria validated hypertonic saline-stimulated copeptin measurement as a diagnostic method that appeared to be superior to the indirect water-deprivation test in distinguishing central diabetes insipidus from primary polydipsia," the authors write.
The researchers found that the full-dose nut diet provided 9.2% greater total energy intake from monounsaturated fat compared with the full-dose muffin diet.
In this retrospective cohort study, for patients with type 2 diabetes, initiation of a basal insulin analog compared with NPH insulin was not associated with a reduced risk of hypoglycemia-related ED visits or hospital admissions.
The researchers found that more than 2 million older adults with diabetes (25.0%) used some form of CAM in the past year in 2012.
The new Flash Glucose Monitoring System enables patients to wear the sensor for up to 14 days compared with the existing FreeStyle Libre System that was approved for 10-day wear.
The researchers found that over a mean follow-up of 1.1 years, sulfonylureas were associated with an increased risk of myocardial infarction, all-cause mortality, and severe hypoglycemia vs continuing metformin monotherapy.
The researchers found that in the pooled analysis, bone fracture AEs were reported in 119 of 4221 patients (2.8%) randomized to empagliflozin 10mg, 105 of 4,196 patients (2.5%) randomized to empagliflozin 25mg, and 123 of 4203 patients (2.9%) randomized to the placebo group.
Approximately 12,000 patients took part in the CAMELLIA-TIMI 61 trial in which participants were randomized to either lorcaserin HCl 10mg twice daily or placebo.
In the AWARD-7 trial, patients who received Trulicity 0.75mg or 1.5mg in combination with mealtime insulin lispro achieved similar glycemic control with weight loss vs patients who received traditional basal-bolus insulin.
Results showed the overall safety profile of linagliptin in study patients, including adults with kidney disease, was consistent with previous data.
Thrice-weekly degludec (Deg-3TW) was inferior to most other regimens for reducing glycated hemoglobin levels, according to low- to very-low-quality evidence.
A clinical trial assessing canagliflozin (Invokana; Janssen) as an addition to standard-of-care in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) has been stopped early after meeting its pre-specified efficacy criteria.
The application also includes the fixed-dose combinations, Invokamet (canagliflozin, metformin tablets) and Invokamet XR (canagliflozin, metformin extended-release tablets).
The researchers observed no significant differences between treatment groups at baseline, 12 months, or 15 months in β-cell function, body mass index (BMI) percentile, hemoglobin A1c (HbA1c), fasting glucose, or oral glucose tolerance test 2-hour glucose results.
The researchers found that circadian phase and circadian misalignment impact glucose tolerance through different mechanisms.
The labeling changes are based on a review of postmarketing adverse event reports found in the FDA Adverse Event Reporting System (FAERS) database and published medical literature.
For this study, researchers conducted a randomized, double-blind, placebo-controlled Phase 2 trial (N=24) to assess the efficacy and safety of adding oral verapamil for 12 months to a standard insulin regimen in adults with recent-onset type 1 diabetes (age range: 18 to 45 years).